Amarillo Biosciences Inc. (OTCMKTS:AMAR) issued its quarterly earnings data on Monday. The company reported ($0.01) earnings per share for the quarter, Bloomberg Earnings reports.

Amarillo Biosciences (OTCMKTS:AMAR) opened at $0.23 on Wednesday. Amarillo Biosciences has a fifty-two week low of $0.15 and a fifty-two week high of $0.30.

In related news, CEO Stephen T. Chen purchased 203,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average price of $0.19 per share, with a total value of $38,570.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders purchased a total of 230,739 shares of company stock worth $46,030 in the last three months.

ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/22/amarillo-biosciences-inc-amar-releases-earnings-results.html.

Amarillo Biosciences Company Profile

Amarillo Biosciences, Inc is engaged in the business of biopharmaceutical research and development. The Company develops biologics for the treatment of human and animal diseases. The Company’s focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia and other indications using natural human interferon alpha that is administered in a low dose oral form.

Receive News & Ratings for Amarillo Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.